Alnylam Pharmaceuticals (ALNY)
(Delayed Data from NSDQ)
$147.36 USD
+4.05 (2.83%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $147.46 +0.10 (0.07%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum B VGM
Brokerage Reports
0 items in cart
Alnylam Pharmaceuticals, Inc. [ALNY]
Reports for Purchase
Showing records 361 - 380 ( 406 total )
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
We are initiating coverage with a Buy rating and a target price of $12.
Provider: RODMAN & RENSHAW, CO.
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
We are placing Alnylam Pharmaceuticals Under Review due to the departure from the firm of analyst, Simos Simeonidis
Provider: RODMAN & RENSHAW, CO.
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
We are placing Alnylam Pharmaceuticals Under Review due to the departure from the firm of analyst, Simos Simeonidis
Provider: RODMAN & RENSHAW, CO.
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
LIFE SCIENCESThis report contains brief updates on the following: SUPG, DNDN, SPPI, ALNY, ROSG, ZIOP. These companies are covered in more detail in separate Daily Notes and/or Company Reports.
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
R&Rs Week in Review: Oncology and Stem Cell Sectors
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
R&Rs Week in Review: Oncology and Stem Cell Sectors.
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Oversold in reaction to Roche and Novartis moves; short- and long-term buying
Provider: RODMAN & RENSHAW, CO.
Analyst: SIMEONIDIS S
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.